Trial Profile
Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 23 Mar 2023 Status changed from active, no longer recruiting to completed.
- 12 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2022 Planned End Date changed from 31 Aug 2022 to 31 Jan 2023.